Author: Benzinga Insights

FL – Foot Locker: Q2 Earnings Insights

Written by Benzinga Insights on . Posted in FL, Stock Report.

Shares of Foot Locker (NYSE:FL) rose 6.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 211.27% over the past year to $2.21, which beat the estimate of $1.00.

Revenue of $2,275,000,000 higher by 9.53% from the same period last year, which beat the estimate of $2,090,000,000.

Guidance

Foot Locker will provide FY21 guidance on call.

How To Listen To The Conference Call

Date: Aug 20, 2021

Time: 09:00 AM

ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=OOCLuTNU

Technicals

52-week high: $66.71

52-week low: $26.90

Price action over last quarter: down 5.77%

Company Profile

Foot Locker Inc operates thousands of retail stores throughout the United States, Canada, Europe, Australia, and New Zealand. It also has one franchisee in the Middle East and one in South Korea, each of which operates multiple stores in those regions. The company mainly sells athletically inspired shoes and apparel. Foot Locker’s merchandise comes from only a few suppliers, with Nike providing the majority. Store names include Foot Locker, Champs, and Runners Point. The company also has an e-commerce business selling through Footlocker.com, Eastbay, and Final-Score.

JKHY – Jack Henry & Associates: Q4 Earnings Insights

Written by Benzinga Insights on . Posted in JKHY, Stock Report.

Shares of Jack Henry & Associates (NASDAQ:JKHY) moved higher by 0.5% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 30.00% over the past year to $1.04, which beat the estimate of $0.93.

Revenue of $450,287,000 rose by 9.68% from the same period last year, which beat the estimate of $445,120,000.

Outlook

Jack Henry & Associates hasn’t issued any earnings guidance for the time being.

Revenue guidance hasn’t been issued by the company for now.

Price Action

Company’s 52-week high was at $200.98

52-week low: $141.65

Price action over last quarter: Up 12.62%

Company Overview

Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for U.S. banks and credit unions, with a focus on small and midsize banks. Jack Henry serves about 1,000 banks and 800 credit unions.

CREE – Recap: Cree Q4 Earnings

Written by Benzinga Insights on . Posted in CREE, Stock Report.

Shares of Cree (NASDAQ:CREE) fell 5.7% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 27.78% year over year to ($0.23), which beat the estimate of ($0.24).

Revenue of $145,800,000 declined by 29.12% year over year, which beat the estimate of $145,170,000.

Looking Ahead

Q1 EPS expected to be between ($0.25) and ($0.21).

Q1 revenue expected to be between $144,000,000 and $154,000,000.

Details Of The Call

Date: Aug 17, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/oqdhenz7

Recent Stock Performance

52-week high: $129.90

Company’s 52-week low was at $56.39

Price action over last quarter: down 16.27%

Company Description

Cree Inc is a United States-based company which is involved in the manufacturing of wide bandgap semiconductor products for power and radio-frequency (RF) applications, lighting-class light-emitting diode (LED) products, and lighting products. It operates in two reportable segments: Wolfspeed and LED products. The Wolfspeed segment’s products consist of silicon carbide and gallium nitride materials, power devices and RF devices based on silicon and wide bandgap semiconductor materials. The LED products segment, which is the key revenue driver, consist of LED chips and LED components. Geographically, the company conducts business in the United States, China, Europe, and other areas.

QUIK – QuickLogic: Q2 Earnings Insights

Written by Benzinga Insights on . Posted in QUIK, Stock Report.

Shares of QuickLogic (NASDAQ:QUIK) remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share increased 38.46% year over year to ($0.16), which missed the estimate of ($0.15).

Revenue of $2,882,000 rose by 31.24% from the same period last year, which beat the estimate of $2,800,000.

Guidance

QuickLogic hasn’t issued any earnings guidance for the time being.

Revenue guidance hasn’t been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 17, 2021

Time: 05:30 PM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/46185/indexl.html

Technicals

Company’s 52-week high was at $12.49

52-week low: $2.52

Price action over last quarter: down 11.52%

Company Profile

QuickLogic Corp is engaged in the development and marketing of semiconductor and software algorithm solutions for mobile and portable electronics. The company’s products enable smartphone, wearable and IoT device Original Equipment Manufacturers, or OEMs, to deliver long battery life for their customers. Its solutions fall into one of three categories: Sensor Processing, Display and Visual Enhancement, and Smart connectivity. Geographically, it has a presence in the Asia Pacific, Europe, and North America. It also works with mobile processor manufacturers, sensor manufacturers, sensor fusion and context awareness algorithm developers in the development of reference designs, Qualified Vendor Lists, or QVLs, or Catalog solutions.

A – Recap: Agilent Technologies Q3 Earnings

Written by Benzinga Insights on . Posted in A, Stock Report.

Shares of Agilent Technologies (NYSE:A) fell 0.6% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 41.03% year over year to $1.10, which beat the estimate of $0.99.

Revenue of $1,586,000,000 rose by 25.77% year over year, which beat the estimate of $1,540,000,000.

Guidance

Q4 EPS expected between $1.15 and $1.18.

Q4 revenue expected to be between $1,630,000,000 and $1,660,000,000.

Conference Call Details

Date: Aug 17, 2021

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.investor.agilent.com%2F&eventid=3190663&sessionid=1&key=B5CA9083735D727B3F9803B404F9885E&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company’s 52-week high was at $162.52

52-week low: $94.53

Price action over last quarter: Up 20.86%

Company Overview

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent’s measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2020 sales), cross lab (36% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Just over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (33%) and China (20%) representing the largest country concentrations.

IMMR – Immersion: Q2 Earnings Insights

Written by Benzinga Insights on . Posted in IMMR, Stock Report.

Shares of Immersion (NASDAQ:IMMR) rose 2.1% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 666.67% year over year to $0.23, which beat the estimate of $0.16.

Revenue of $11,010,000 higher by 94.25% from the same period last year, which beat the estimate of $9,370,000.

Guidance

Immersion hasn’t issued any earnings guidance for the time being.

Revenue guidance hasn’t been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 16, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/cesjhxyh

Technicals

Company’s 52-week high was at $16.64

Company’s 52-week low was at $6.10

Price action over last quarter: down 6.33%

Company Overview

Immersion Corp is focused on the creation, design, development, and licensing of innovative haptic technologies that allow people to use its sense of touch more fully as they engage with products and experience the digital world. The company’s software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Korea.

RMTI – Recap: Rockwell Medical Q2 Earnings

Written by Benzinga Insights on . Posted in RMTI, Stock Report.

Shares of Rockwell Medical (NASDAQ:RMTI) fell 12.6% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 0.00% over the past year to ($0.09), which missed the estimate of ($0.08).

Revenue of $15,137,000 decreased by 4.77% from the same period last year, which missed the estimate of $18,210,000.

Outlook

Earnings guidance hasn’t been issued by the company for now.

Revenue guidance hasn’t been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 16, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/wr36t84i

Price Action

Company’s 52-week high was at $1.98

52-week low: $0.65

Price action over last quarter: down 36.31%

Company Description

Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company’s drug products are Triferic. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The company operates in one segment of the hemodialysis market which involves the manufacture, sale, and distribution of hemodialysis products. The majority of the revenue is generated from the United States.

GERN – Recap: Geron Q2 Earnings

Written by Benzinga Insights on . Posted in GERN, Stock Report.

Shares of Geron (NASDAQ:GERN) rose 2.5% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 50.00% over the past year to ($0.09), which missed the estimate of ($0.08).

Revenue of $107,000 up by 148.84% from the same period last year, which beat the estimate of $60,000.

Outlook

Earnings guidance hasn’t been issued by the company for now.

Geron hasn’t issued any revenue guidance for the time being.

Details Of The Call

Date: Aug 16, 2021

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=http%3A%2F%2Fir.geron.com%2F&eventid=3192629&sessionid=1&key=59DF391C57E9902656F40690D9750AE3&regTag=&V2=false&sourcepage=register

Price Action

Company’s 52-week high was at $2.35

Company’s 52-week low was at $1.20

Price action over last quarter: down 10.07%

Company Profile

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company’s leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

HCKT – The Hackett Group: Q2 Earnings Insights

Written by Benzinga Insights on . Posted in HCKT, Stock Report.

Shares of The Hackett Group (NASDAQ:HCKT) moved higher in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 550.00% over the past year to $0.39, which beat the estimate of $0.29.

Revenue of $73,197,000 higher by 38.76% from the same period last year, which beat the estimate of $65,280,000.

Looking Ahead

Q3 EPS expected to be between $0.28 and $0.30.

Q3 revenue expected between $66,000,000 and $68,000,000.

Details Of The Call

Date: Aug 10, 2021

Time: 05:00 PM

ET Webcast URL: https://www.thehackettgroup.com/events/

Technicals

Company’s 52-week high was at $18.94

Company’s 52-week low was at $11.05

Price action over last quarter: Up 7.24%

Company Profile

The Hackett Group Inc is an advisory firm. The company’s offerings include executive advisory programs, benchmarking, business transportation, and technology advisory services. The company’s executive and practices advisory programs offer performance metrics, peer-learning opportunities, and practice implementation practices. Benchmarking services help organizations measure and assess internal efficiency and effectiveness. The business transformation programs help customers develop strategies to improve performance. The company’s technology advisory services help clients improve decision-making capabilities and deploy software applications. The Hackett Group generates the majority of its revenue in the United States.

ALPN – Alpine Immune Sciences: Q2 Earnings Insights

Written by Benzinga Insights on . Posted in ALPN, Stock Report.

Shares of Alpine Immune Sciences (NASDAQ:ALPN) moved higher in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 13.21% year over year to ($0.46), which missed the estimate of ($0.40).

Revenue of $7,193,000 rose by 945.49% year over year, which beat the estimate of $6,480,000.

Guidance

Alpine Immune Sciences hasn’t issued any earnings guidance for the time being.

Alpine Immune Sciences hasn’t issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 10, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/nkbmxcne

Price Action

52-week high: $16.37

Company’s 52-week low was at $6.66

Price action over last quarter: down 22.32%

Company Profile

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company’s proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.

Copyright 2010. Elite Stock Chat. All Rights Reserved